Pancreatic Elastase Testing Market Outlook:
Pancreatic Elastase Testing Market size was valued at USD 17.8 billion in 2025 and is projected to reach USD 36.9 billion by the end of 2035, rising at a CAGR of 7.9% during the forecast period, i.e., 2026-2035. In 2026, the industry size of the pancreatic elastase testing is estimated at USD 19.3 billion.
There has been an increased awareness and diagnosis of pancreatic insufficiency, particularly among patients with chronic pancreatitis, cystic fibrosis, and other gastrointestinal disorders, which are the key factors propelling growth in the pancreatic elastase testing industry. In this regard, the National Institute of Health in June 2023 revealed that acute pancreatitis leads to around 275,000 hospital admissions in a year, wherein 80% of cases are mild and a mortality rate of about 2%. It also stated that chronic pancreatitis affects 50 per 100,000 people, with an annual incidence of 5 to 12 per 100,000.
Furthermore, the growing focus on early detection and preventive healthcare is driving adoption in this field, especially in regions with expanding healthcare infrastructure. A study by the NIH in January 2025 observed that the ambulatory care cost breakdown for the cohort shows significant differences between the U.S. and Ireland. It further found that the U.S. is dominating at 81.41% of the total laboratory costs, wherein Ireland reported at 40.35%, and higher proportions in radiology and procedures.
